万古霉素与达托霉素在门诊肠外抗菌治疗中的医疗资源利用及成本比较
: Comparison of Vancomycin and Daptomycin Health Care Utilization and Cost in Outpatient Parenteral Antimicrobial Therapy.
作者信息
Streifel Amber C, Luis Katie, Nakrani Monark, Yu Diana, Sikka Monica K, Varley Cara D, Douglass Alyse, Mayer Heather, Young Kathleen, Lewis James S
机构信息
Department of Pharmacy, Oregon Health & Science University, Portland, Oregon, USA.
Division of Infectious Diseases, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
出版信息
Open Forum Infect Dis. 2024 Jul 25;11(8):ofae438. doi: 10.1093/ofid/ofae438. eCollection 2024 Aug.
Abstract
Vancomycin and daptomycin are frequently used in outpatient parenteral antimicrobial therapy (OPAT). We analyze health care utilization and cost to the health care system for vancomycin vs daptomycin in the outpatient setting and find that vancomycin results in significantly higher health care utilization and similar cost per course compared with daptomycin in OPAT.
摘要
万古霉素和达托霉素常用于门诊胃肠外抗菌治疗（OPAT）。我们分析了门诊环境中使用万古霉素与达托霉素时的医疗保健利用率及医疗保健系统成本，发现与达托霉素相比，万古霉素导致显著更高的医疗保健利用率，且在OPAT中每疗程成本相近。
相似文献
1
: Comparison of Vancomycin and Daptomycin Health Care Utilization and Cost in Outpatient Parenteral Antimicrobial Therapy.万古霉素与达托霉素在门诊肠外抗菌治疗中的医疗资源利用及成本比较
Open Forum Infect Dis. 2024 Jul 25;11(8):ofae438. doi: 10.1093/ofid/ofae438. eCollection 2024 Aug.
2
Adverse events, healthcare interventions and healthcare utilization during home infusion therapy with daptomycin and vancomycin: a propensity score-matched cohort study.达托霉素和万古霉素家庭输注治疗期间的不良事件、医疗保健干预措施及医疗保健利用情况：一项倾向评分匹配队列研究
J Antimicrob Chemother. 2014 May;69(5):1407-15. doi: 10.1093/jac/dkt512. Epub 2014 Jan 6.
3
A retrospective analysis of adverse events among patients receiving daptomycin versus vancomycin during outpatient parenteral antimicrobial therapy.接受达托霉素与万古霉素门诊患者的药物不良反应回顾性分析。
Infect Control Hosp Epidemiol. 2018 Aug;39(8):947-954. doi: 10.1017/ice.2018.107. Epub 2018 Jun 12.
4
Inpatient Antibiotic Costs Associated With Switching From Vancomycin to Daptomycin for Outpatient Parenteral Antibiotic Therapy.因门诊肠外抗生素治疗从万古霉素换用达托霉素而产生的住院抗生素费用。
Hosp Pharm. 2022 Feb;57(1):17-19. doi: 10.1177/0018578720970466. Epub 2020 Nov 6.
5
Vancomycin or Daptomycin for Outpatient Parenteral Antibiotic Therapy: Does It Make a Difference in Patient Satisfaction?门诊静脉用抗生素治疗中使用万古霉素或达托霉素：这对患者满意度有影响吗？
Open Forum Infect Dis. 2021 Aug 30;8(8):ofab418. doi: 10.1093/ofid/ofab418. eCollection 2021 Aug.
6
Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin.耐甲氧西林金黄色葡萄球菌复杂性皮肤和软组织感染的住院及门诊抗生素治疗的经济负担：利奈唑胺、万古霉素和达托霉素的比较
Clinicoecon Outcomes Res. 2013 Sep 16;5:447-57. doi: 10.2147/CEOR.S46991. eCollection 2013.
7
Antimicrobial stewardship in the outpatient parenteral antimicrobial therapy (OPAT) setting: the impact of prescription assessment by an infectious diseases specialist.门诊患者的抗菌药物管理（OPAT）：传染病专家处方评估的影响。
Braz J Infect Dis. 2021 Mar-Apr;25(2):101560. doi: 10.1016/j.bjid.2021.101560. Epub 2021 Mar 11.
8
Evaluation of Inpatient Antimicrobial Regimens for Readmitted Outpatient Parenteral Antimicrobial Therapy Patients Receiving Daptomycin or Ertapenem for Ease of Administration.对因给药便利性而接受达托霉素或厄他培南治疗的再入院门诊胃肠外抗菌治疗患者的住院抗菌治疗方案的评估。
Open Forum Infect Dis. 2019 Nov 19;6(12):ofz496. doi: 10.1093/ofid/ofz496. eCollection 2019 Dec.
9
Recent Updates in Antimicrobial Stewardship in Outpatient Parenteral Antimicrobial Therapy.门诊胃肠外抗菌治疗中抗菌药物管理的最新进展
Curr Infect Dis Rep. 2021;23(12):24. doi: 10.1007/s11908-021-00766-x. Epub 2021 Nov 9.
10
Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin.欧洲革兰氏阳性菌感染的门诊胃肠外抗菌治疗（OPAT）的进展以及达托霉素的潜在影响
J Antimicrob Chemother. 2009 Sep;64(3):447-53. doi: 10.1093/jac/dkp245. Epub 2009 Jul 7.
引用本文的文献
1
Are Oritavancin and Dalbavancin More Cost Effective for Outpatient Parenteral Antimicrobial Therapy at a Veterans Affairs Medical Center?在一家退伍军人事务医疗中心，奥利万星和达巴万星用于门诊胃肠外抗菌治疗时成本效益更高吗？
Fed Pract. 2025 Jun;42(6):236-243b. doi: 10.12788/fp.0571. Epub 2025 Jun 17.
2
Incidence and risk factors for musculoskeletal adverse effects associated with daptomycin in patients receiving outpatient parenteral antimicrobial therapy.接受门诊胃肠外抗菌治疗的患者中，与达托霉素相关的肌肉骨骼不良反应的发生率及危险因素。
Antimicrob Steward Healthc Epidemiol. 2025 Jul 31;5(1):e169. doi: 10.1017/ash.2025.10087. eCollection 2025.
本文引用的文献
1
Counting the Cost of Daptomycin Versus Vancomycin in Hospitalized Patients: A Cost Minimization Analysis.住院患者中达托霉素与万古霉素的成本核算：成本最小化分析
Open Forum Infect Dis. 2024 Apr 18;11(5):ofae217. doi: 10.1093/ofid/ofae217. eCollection 2024 May.
2
Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.针对耐甲氧西林金黄色葡萄球菌严重感染的万古霉素治疗监测：美国卫生系统药师协会、美国传染病学会、儿科传染病学会及传染病药师学会的修订共识指南及综述
Am J Health Syst Pharm. 2020 May 19;77(11):835-864. doi: 10.1093/ajhp/zxaa036.
3
Risk factors for readmission in patients discharged with outpatient parenteral antimicrobial therapy: a retrospective cohort study.接受门诊胃肠外抗菌治疗出院患者再入院的危险因素：一项回顾性队列研究。
BMC Pharmacol Toxicol. 2018 Aug 6;19(1):50. doi: 10.1186/s40360-018-0240-3.
4
A retrospective analysis of adverse events among patients receiving daptomycin versus vancomycin during outpatient parenteral antimicrobial therapy.接受达托霉素与万古霉素门诊患者的药物不良反应回顾性分析。
Infect Control Hosp Epidemiol. 2018 Aug;39(8):947-954. doi: 10.1017/ice.2018.107. Epub 2018 Jun 12.
5
Rates of and Risk Factors for Adverse Drug Events in Outpatient Parenteral Antimicrobial Therapy.门诊肠外抗菌治疗药物不良事件的发生率和危险因素。
Clin Infect Dis. 2018 Jan 6;66(1):11-19. doi: 10.1093/cid/cix733.
6
Clinical efficacy, cost analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield (UK) OPAT service.门诊静脉用抗生素治疗 (OPAT) 的临床疗效、成本分析和患者接受度：谢菲尔德（英国）OPAT 服务十年来的经验。
Int J Antimicrob Agents. 2018 Jan;51(1):26-32. doi: 10.1016/j.ijantimicag.2017.03.016. Epub 2017 Jun 30.
7
Patient satisfaction in an outpatient parenteral antimicrobial therapy (OPAT) unit practising predominantly self-administration of antibiotics with elastomeric pumps.门诊肠外抗菌治疗（OPAT）单元中以弹性泵自我给药为主的患者满意度。
Eur J Clin Microbiol Infect Dis. 2017 Aug;36(8):1387-1392. doi: 10.1007/s10096-017-2944-5. Epub 2017 Mar 11.
8
Vascular access complications during outpatient parenteral antimicrobial therapy at home: a retrospective cohort study.门诊患者在家接受胃肠外抗菌治疗期间的血管通路并发症：一项回顾性队列研究
J Antimicrob Chemother. 2016 Feb;71(2):506-12. doi: 10.1093/jac/dkv344. Epub 2015 Oct 28.
9
Adverse events, healthcare interventions and healthcare utilization during home infusion therapy with daptomycin and vancomycin: a propensity score-matched cohort study.达托霉素和万古霉素家庭输注治疗期间的不良事件、医疗保健干预措施及医疗保健利用情况：一项倾向评分匹配队列研究
J Antimicrob Chemother. 2014 May;69(5):1407-15. doi: 10.1093/jac/dkt512. Epub 2014 Jan 6.
10
Vancomycin: a 50-year reassessment.万古霉素：50年再评估
Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S3-4. doi: 10.1086/491708.
Zotero 插件